Development of a highly sensitive serological assay for Covid-19 based on the use of virus-like particles and protein-based nanoparticles.

基于使用病毒样颗粒和基于蛋白质的纳米颗粒，开发针对 Covid-19 的高灵敏度血清学检测。

• 批准号: BB/V006584/1
• 负责人: Polly Roy
• 金额: $ 48.48万
• 依托单位: London School of Hygiene & Tropical Medicine
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FV006584%2F1
• 关键词: Development; highly; sensitive; serological; assay

We propose to use the baculovirus expression system to generate Virus-Like Particles (VLPs) mimicking the recently emergent SARS-CoV-2. We have previously co-expressed three essential structural proteins (S, M, and E) of SARS-CoV using a single baculovirus expression vector developed in our lab and demonstrated that when co-expressed in Sf9 cells, these three proteins were able to spontaneously adopt a conformation mimicking the full virus (1). Subsequent mouse studies showed that vaccination with these elicited a strong neutralising antibody response, equivalent to that seen in a convalescent human. Recently we used these pre-existing reagents as a basis to produce SARS-CoV-2 VLPs, substituting the S, M, and E proteins into the previously generated Baculovirus constructs, and preliminary data shows that all three SARS-CoV-2 proteins are expressed. We propose to characterise thoroughly the expressed proteins, the formation of VLPs, and the immune response in mice to validate their authenticity as virus mimics. VLPs will be ultimately used to develop an antibody detection assay. In parallel, we will express the SARS-CoV-2 Fc-tagged S protein alone to be externally encapsulated with the lumazine synthase protein-based nanoparticles (PNPs) that we have already prepared. We have shown that similar nanoparticles for a receptor binding protein of a different virus enhanced binding affinity and avidity. These PNPs self-assemble into hollow monodisperse spherical structures, which stabilises the trimeric S protein and enhances antigenicity (2). Both SARS-CoV-2 VLPs and PNPs are excellent candidates for the development of highly sensitive diagnostic assay that will be used to detect COVID-19 infected human sera.

我们建议使用杆状病毒表达系统生成模拟最近出现的SARS-CoV-2的病毒样颗粒（vlp）。我们之前使用实验室开发的单个杆状病毒表达载体共表达了SARS-CoV的三种基本结构蛋白（S， M和E），并证明当在Sf9细胞中共表达时，这三种蛋白能够自发地采用模拟完整病毒的构象(1)。随后的小鼠研究表明，接种这些疫苗会引起强烈的中和抗体反应，相当于在恢复期的人身上看到的反应。最近，我们以这些已有的试剂为基础，将S、M和E蛋白替换到先前生成的杆状病毒构建物中，产生了SARS-CoV-2 VLPs，初步数据显示，这三种SARS-CoV-2蛋白都得到了表达。我们建议在小鼠中彻底表征表达蛋白、VLPs的形成和免疫反应，以验证它们作为病毒模拟物的真实性。VLPs最终将用于开发抗体检测分析。同时，我们将单独表达SARS-CoV-2 fc标记的S蛋白，并将其与我们已经制备的基于lumazine synthase蛋白的纳米颗粒（PNPs）包裹在外部。我们已经证明，不同病毒的受体结合蛋白的类似纳米颗粒增强了结合亲和力和亲和度。这些PNPs自组装成中空的单分散球形结构，从而稳定了三聚体S蛋白并增强了抗原性(2)。SARS-CoV-2 VLPs和PNPs都是开发用于检测COVID-19感染的人血清的高灵敏度诊断检测的优秀候选者。

项目成果

SARS-CoV-2 Virus like Particles produced by a single recombinant baculovirus generate potent neutralizing antibody that protects against variant challenge

• DOI: 10.1101/2021.11.29.470349
• 发表时间: 2021-11
• 期刊: bioRxiv
• 作者: Edward Sullivan;Po-Yu Sung;Weining Wu;N. Berry;S. Kempster;D. Ferguson;N. Almond;I. Jones;P. Roy

Sputnik V COVID-19 vaccine candidate appears safe and effective.

• DOI: 10.1016/s0140-6736(21)00191-4
• 发表时间: 2021-02-20
• 期刊: Lancet (London, England)
• 作者: Jones I;Roy P
• 通讯作者: Roy P